Modus Therapeutics Holding AB (publ)

Stockholm Stock Exchange MODTX.ST

Modus Therapeutics Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2023: 17,745,000

Modus Therapeutics Holding AB (publ) Shares (Diluted, Weighted) is 17,745,000 for the year ending December 31, 2023, a 10.22% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
  • Modus Therapeutics Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2022 was 16,100,000, a 30.09% change year over year.
  • Modus Therapeutics Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2021 was 12,376,000.
  • Modus Therapeutics Holding AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2019 was 16,100,050, a 0.00% change year over year.
Key data
Date Shares (Diluted, Weighted) Revenue Cost of Revenue Gross Profit
Market news
SV Wall Street
Stockholm Stock Exchange: MODTX.ST

Modus Therapeutics Holding AB (publ)

CEO Dr. John Öhd M.D., Ph.D.
IPO Date July 22, 2021
Location Sweden
Headquarters Olof Palmes gata 29 IV
Employees 2
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals Plastics Vaccines
Description

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.

StockViz Staff

February 4, 2025

Any question? Send us an email